Form 4: Coeptis VP Acquires Shares, Exchanges Underwater Options

Coeptis Therapeutics Holdings VP of Compliance and Secretary, Christine Elise Sheehy, increased her direct beneficial ownership through option exercise and a restricted stock grant.

Summary

• Christine Elise Sheehy, VP Compliance and Secretary of Coeptis Therapeutics Holdings, Inc. (COEP), reported transactions increasing her beneficial ownership.
• On February 11, 2026, Sheehy acquired 1,000 shares of common stock through the exercise of stock options at a price of $10.56 per share.
• Also on February 11, 2026, Sheehy received a grant of 12,500 shares of restricted stock at a price of $0 per share.
• This restricted stock grant was issued as part of an option exchange program where Sheehy surrendered previously underwater options.
• Following these transactions, Sheehy directly beneficially owns a total of 64,031 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While the 'underwater options' context suggests past stock underperformance, the increase in insider ownership and the re-incentivization of a key executive are generally favorable for future alignment.

Positives

• Increased insider ownership by a key executive, Christine Elise Sheehy, who now directly holds 64,031 shares.
• The grant of restricted stock incentivizes management, aligning their interests with shareholders, particularly after surrendering underwater options.
• Transactions were pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to equity management.

Negatives

• The restricted stock grant was in exchange for 'underwater options,' suggesting that previous stock options held by the executive were out-of-the-money, which could reflect past underperformance of the company's stock price.

Risks

• No specific risks were mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, as it is a report of past and pre-planned insider transactions.

Industry Context

StockSavvy.ai notes that insider transaction reports like Form 4 are routine disclosures in the biotechnology and pharmaceutical sectors. The exchange of underwater options for restricted stock is a common practice used by companies to re-incentivize executives when stock prices have declined, aiming to retain talent and realign compensation with future performance. This is particularly relevant in a volatile sector like therapeutics where R&D outcomes can significantly impact stock valuation.

Comparison to Industry Standards

• The use of restricted stock grants to replace underwater options is a standard executive compensation strategy across various industries, including biotech, to maintain executive motivation and retention.
• Many companies, such as Moderna (MRNA) or Pfizer (PFE), utilize similar equity compensation structures to align executive interests with long-term shareholder value, especially after periods of stock price volatility.

Stakeholder Impact

• Shareholders: The increase in insider ownership by a key executive may be viewed positively as it aligns management's interests with shareholder value. The re-incentivization through restricted stock aims to motivate the executive for future performance.
• Employees: No direct impact on general employees is indicated, but executive compensation practices can influence overall company morale and retention strategies.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions, including an option exercise and a restricted stock grant in exchange for underwater options. While it shows continued insider alignment and re-incentivization, it does not present new fundamental information significant enough to warrant a change in investment thesis. The 'underwater options' context suggests past stock underperformance, which is a minor negative, but the overall increase in beneficial ownership is a slight positive. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a strong catalyst for a 'buy' or 'sell' decision.

Keywords

Coeptis Therapeutics, COEP, Insider Trading, Form 4, Stock Options, Restricted Stock, Executive Compensation, Christine Elise Sheehy, Rule 10b5-1